India, Dec. 19 -- Immix Biopharma, Inc. (IMMX), a clinical-stage biopharmaceutical company, on Thursday, announced encouraging early results from the first four patients in its ongoing Phase 1b/2 NEXICART-2 U.S. trial of NXC-201 for the treatment of relapsed/refractory Light Chain (AL) Amyloidosis.
The NEXICART-2 trial is the only ongoing clinical trial of a CAR-T therapy in the U.S. for AL Amyloidosis.
The trial is designed to evaluate NXC-201 in relapsed/refractory patients with preserved heart function. The company believes these early results validate its approach and expects future complete responders.
The study demonstrated that all four patients who received NXC-201 normalized their disease markers within 30 days of treatment. Of ...